Speaking at a meeting of the Economic Club in Washington, D.C., Mr. Ricks described the drugs as “anti-hedonics,” potentially offering patients relief from dependence by reducing cravings.
The company plans to begin large-scale clinical trials next year focusing on alcohol and nicotine use and potentially drug abuse as part of an effort to explore broader therapeutic applications of its weight loss treatments.
Rival drugmaker Novo Nordisk has also expressed interest in studying its weight loss medications’ impact on alcohol consumption, saying earlier this year that it was planning a study.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
